Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite a modest market size – continues to hold global relevance for the group.
Moving beyond the traditional pharma-government dialogue around payment and access for innovation, we are exploring alternative partnerships with public and private stakeholders to invest in health and get people’s diabetes or obesity under control
